Cloud migration to accelerate drug discovery with AWS
Context
Owkin is a leading biotechnology company specializing in the application of Artificial Intelligence (AI) and Machine Learning (ML) for drug discovery.
Owkin wishes to stablish a strong partnership with AWS, a pivotal step in Owkin's mission to focus on its core competency of developing high-value algorithms for advancing medical research and pharmaceutical development.
Owkin aims to significantly expand its market share and fully leverage the capabilities of AWS, particularly the AWS Marketplace and Amazon SageMaker platforms.
Aneo provided technical and organizational support to help Owkin effectively migrate to AWS.
The primary objective for ANEO was to lay a robust foundation for Owkin's migration and integration into AWS's ecosystem.
This migration include setting up a Landing Zone in AWS with a Hub-And-Spoke architecture.
Objectives
- Build a secure, scalable and hight available architecture in AWS for Owkin workloads consisting in Kubernetes applications.
- The limited timeframe, as Owkin wiches to move to AWS as fast as possible in a 3.5-month timeframe.
- Securely transfer hundrends of Terabytes of data from Google Cloud Plateform (GCP) to Amazon Web Services (AWS).
- Reduce cloud charges for Owkin.
- Onboard Owkin's data scientists to Amazon SageMaker and provide framework of development, training and best practices to use Amazon SageMaker.
Results
- A scalable, secure, reliable, optimized and highly available architecture on AWS.
- Data transfered securely to AWS.
- Migration done in the 3.5-month timeframe.
- Advanced FinOps supported by Serverless services.
- Effeciently onboard users to Amazon SageMaker and provide documentations and training materials.